IL286403B2 - Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene - Google Patents

Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene

Info

Publication number
IL286403B2
IL286403B2 IL286403A IL28640321A IL286403B2 IL 286403 B2 IL286403 B2 IL 286403B2 IL 286403 A IL286403 A IL 286403A IL 28640321 A IL28640321 A IL 28640321A IL 286403 B2 IL286403 B2 IL 286403B2
Authority
IL
Israel
Prior art keywords
human
gene
polypeptide
humanized
rodent
Prior art date
Application number
IL286403A
Other languages
English (en)
Hebrew (he)
Other versions
IL286403B1 (en
IL286403A (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54979926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL286403(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL286403A publication Critical patent/IL286403A/en
Publication of IL286403B1 publication Critical patent/IL286403B1/en
Publication of IL286403B2 publication Critical patent/IL286403B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/12Animals modified by administration of exogenous cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0381Animal model for diseases of the hematopoietic system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
IL286403A 2014-12-05 2015-11-25 Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene IL286403B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087992P 2014-12-05 2014-12-05
PCT/US2015/062614 WO2016089692A1 (en) 2014-12-05 2015-11-25 Non-human animals having a humanized cluster of differentiation 47 gene

Publications (3)

Publication Number Publication Date
IL286403A IL286403A (en) 2021-10-31
IL286403B1 IL286403B1 (en) 2023-06-01
IL286403B2 true IL286403B2 (en) 2023-10-01

Family

ID=54979926

Family Applications (2)

Application Number Title Priority Date Filing Date
IL286403A IL286403B2 (en) 2014-12-05 2015-11-25 Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene
IL252019A IL252019B (en) 2014-12-05 2017-04-30 Non-human animals possessing a cluster of differentiation 47 gene of human origin

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL252019A IL252019B (en) 2014-12-05 2017-04-30 Non-human animals possessing a cluster of differentiation 47 gene of human origin

Country Status (29)

Country Link
US (5) US20160345549A1 (enExample)
EP (4) EP4296278A3 (enExample)
JP (2) JP6730277B2 (enExample)
KR (3) KR102617691B1 (enExample)
CN (2) CN112342197B (enExample)
AR (1) AR102888A1 (enExample)
AU (2) AU2015355328B2 (enExample)
BR (1) BR112017010490A2 (enExample)
CA (1) CA2967834C (enExample)
CY (2) CY1121547T1 (enExample)
DK (3) DK3086637T3 (enExample)
ES (3) ES2969389T3 (enExample)
FI (1) FI3850946T3 (enExample)
HR (3) HRP20190634T1 (enExample)
HU (3) HUE054661T2 (enExample)
IL (2) IL286403B2 (enExample)
LT (3) LT3466255T (enExample)
MX (1) MX2017007293A (enExample)
NZ (2) NZ731471A (enExample)
PL (3) PL3466255T3 (enExample)
PT (3) PT3086637T (enExample)
RS (3) RS61774B1 (enExample)
RU (1) RU2728412C2 (enExample)
SG (2) SG10202103050YA (enExample)
SI (3) SI3086637T1 (enExample)
SM (3) SMT201900178T1 (enExample)
TR (1) TR201903891T4 (enExample)
TW (1) TWI681053B (enExample)
WO (1) WO2016089692A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201903891T4 (tr) 2014-12-05 2019-04-22 Regeneron Pharma Bir insanlaştırılmış farklılaşma kümesi 47 genine sahip olan insan dışı hayvanlar.
HRP20202034T1 (hr) 2014-12-09 2021-02-19 Regeneron Pharmaceuticals, Inc. Neljudske životinje s genom za humanizirani diferencijacijski biljeg cd274
WO2016154299A1 (en) * 2015-03-24 2016-09-29 The Trustees Of Columbia University In The City Of New York Genetic modification of pigs for xenotransplantation
ES2784360T3 (es) 2015-05-29 2020-09-24 Regeneron Pharma Animales no humanos que tienen una interrupción en un locus C9ORF72
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたlymphocyte-activation gene 3遺伝子を有する非ヒト動物
JP6843872B2 (ja) 2016-02-04 2021-03-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 操作されたangptl8遺伝子を有する非ヒト動物
RU2749715C2 (ru) 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Грызуны, характеризующиеся гуманизированным геном tmprss
WO2018031920A1 (en) 2016-08-11 2018-02-15 The Jackson Laboratory Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
WO2018041121A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
CN107815465B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN107815468B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
ES3000677T3 (en) * 2016-09-30 2025-03-03 Regeneron Pharma Rodents having a hexanucleotide repeat expansion in a c9orf72 locus
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
WO2018177441A1 (en) * 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
CN108588126B (zh) * 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
US20210161971A1 (en) * 2017-06-12 2021-06-03 Sinai Health System Allograft tolerance without the need for systemic immune suppression
NZ761568A (en) 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
JP7361031B2 (ja) * 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化trkb遺伝子座を含む非ヒト動物
CN112105260B (zh) 2018-03-26 2023-04-28 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
SMT202400300T1 (it) 2018-07-16 2024-09-16 Regeneron Pharma Modelli di roditori della sindrome ditra e loro utilizzo
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113423831B (zh) 2018-12-20 2023-03-10 瑞泽恩制药公司 核酸酶介导的重复扩增
CN114107385A (zh) * 2019-01-17 2022-03-01 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
WO2021027737A1 (en) * 2019-08-09 2021-02-18 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il2ra
CN112553252B (zh) * 2019-09-06 2022-04-29 百奥赛图(北京)医药科技股份有限公司 Tnfr2基因人源化的非人动物的构建方法和应用
WO2021136537A1 (en) * 2019-12-31 2021-07-08 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα/CD47
CN112080522A (zh) * 2020-09-15 2020-12-15 广东药康生物科技有限公司 一种cd47人源化小鼠模型的构建方法
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
WO2023046061A1 (en) * 2021-09-24 2023-03-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric trop2
CN119654068A (zh) 2022-07-19 2025-03-18 瑞泽恩制药公司 转基因动物模型及其模拟人类免疫系统的用途
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8101719B2 (en) * 2003-11-11 2012-01-24 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US20070113297A1 (en) 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
ES2378407T3 (es) * 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CN101668387A (zh) 2008-09-02 2010-03-10 鸿富锦精密工业(深圳)有限公司 印刷电路板
WO2010082385A1 (ja) * 2009-01-16 2010-07-22 財団法人実験動物中央研究所 ヒト肝細胞が移植されたマウス
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
CA3057650A1 (en) * 2009-09-15 2011-03-24 Irving L. Weissman Synergistic anti-cd47 therapy for hematologic cancers
JP5874881B2 (ja) 2009-10-06 2016-03-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変されたマウスおよび移植方法
EP2675271B1 (en) 2011-02-15 2018-06-13 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
HRP20220616T1 (hr) 2011-10-28 2022-06-24 Regeneron Pharmaceuticals, Inc. Genetski modificirani miš koji eksprimira kimerne molekule glavnog kompleksa histokompatibilnosti (mhc) ii
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
PT2770821T (pt) 2011-10-28 2017-12-18 Regeneron Pharma Ratinhos de complexo principal de histocompatibilidade principal modificados geneticamente
EP2644027A1 (en) * 2012-03-26 2013-10-02 Institut Pasteur Transgenic immunodefficient mouse expressing human SIRPalpha.
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
KR102340059B1 (ko) 2012-09-07 2021-12-17 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
US9901082B2 (en) * 2012-11-05 2018-02-27 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
HK1216647A1 (zh) * 2012-12-12 2016-11-25 Vasculox Inc. 治疗性cd47抗体
KR102369454B1 (ko) 2013-02-20 2022-03-04 리제너론 파아마슈티컬스, 인크. 사람화된 t-세포 보조-수용체를 발현하는 마우스
CN110192541B (zh) 2013-02-22 2022-02-18 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
SG11201601184UA (en) 2013-09-23 2016-03-30 Regeneron Pharma Non-human animals having a humanized signal-regulatory protein gene
US9155290B2 (en) 2013-10-15 2015-10-13 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
CN105792647B (zh) 2013-11-19 2018-10-02 瑞泽恩制药公司 具有人源化的增殖诱导配体基因的非人动物
CN106163273B (zh) 2014-04-08 2020-07-24 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
NO2785538T3 (enExample) 2014-05-07 2018-08-04
KR102821645B1 (ko) 2014-05-19 2025-06-19 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
US10390522B2 (en) 2014-06-19 2019-08-27 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
MX2017006802A (es) 2014-11-24 2018-01-30 Regeneron Pharma Animales no humanos que expresan el complejo cd3 humanizado.
TR201903891T4 (tr) 2014-12-05 2019-04-22 Regeneron Pharma Bir insanlaştırılmış farklılaşma kümesi 47 genine sahip olan insan dışı hayvanlar.

Also Published As

Publication number Publication date
AR102888A1 (es) 2017-03-29
IL252019A0 (en) 2017-06-29
SG11201703463WA (en) 2017-05-30
HRP20210662T1 (hr) 2021-05-28
SI3086637T1 (sl) 2019-04-30
US10939673B2 (en) 2021-03-09
PT3086637T (pt) 2019-03-26
ES2969389T3 (es) 2024-05-17
HUE064960T2 (hu) 2024-04-28
IL286403B1 (en) 2023-06-01
CN107205368B (zh) 2020-11-17
KR102508175B1 (ko) 2023-03-09
KR20170098800A (ko) 2017-08-30
US20210161112A1 (en) 2021-06-03
PL3466255T3 (pl) 2021-08-09
DK3466255T3 (da) 2021-05-03
HRP20231707T1 (hr) 2024-03-15
US10015953B2 (en) 2018-07-10
EP4296278A3 (en) 2024-03-27
LT3466255T (lt) 2021-05-25
KR102617691B1 (ko) 2023-12-27
IL286403A (en) 2021-10-31
RS58536B1 (sr) 2019-04-30
JP2018500012A (ja) 2018-01-11
LT3086637T (lt) 2019-04-10
SI3850946T1 (sl) 2024-02-29
HK1225912A1 (en) 2017-09-22
DK3850946T3 (da) 2024-01-08
RU2017123357A3 (enExample) 2019-06-03
RS61774B1 (sr) 2021-05-31
US11910788B2 (en) 2024-02-27
TR201903891T4 (tr) 2019-04-22
CA2967834C (en) 2024-01-16
ES2870462T3 (es) 2021-10-27
KR20210127773A (ko) 2021-10-22
RS64989B1 (sr) 2024-01-31
US20160157470A1 (en) 2016-06-09
EP3086637A1 (en) 2016-11-02
US20160345549A1 (en) 2016-12-01
AU2022203787B2 (en) 2025-01-30
MX2017007293A (es) 2018-03-12
ES2716735T3 (es) 2019-06-14
HUE054661T2 (hu) 2021-09-28
EP3466255A1 (en) 2019-04-10
PL3086637T3 (pl) 2019-09-30
CN107205368A (zh) 2017-09-26
BR112017010490A2 (pt) 2018-04-03
SMT201900178T1 (it) 2019-05-10
US20240138384A1 (en) 2024-05-02
US20180249689A1 (en) 2018-09-06
SG10202103050YA (en) 2021-05-28
PT3466255T (pt) 2021-05-10
SI3466255T1 (sl) 2021-07-30
TWI681053B (zh) 2020-01-01
FI3850946T3 (fi) 2023-12-28
CN112342197B (zh) 2025-02-18
KR20230038599A (ko) 2023-03-20
TW201629210A (zh) 2016-08-16
JP2020168016A (ja) 2020-10-15
IL252019B (en) 2021-10-31
AU2022203787A1 (en) 2022-06-23
EP4296278A2 (en) 2023-12-27
SMT202100281T1 (it) 2021-07-12
NZ769992A (en) 2024-11-29
EP3086637B1 (en) 2019-01-02
JP7089554B2 (ja) 2022-06-22
AU2015355328A1 (en) 2017-05-18
PL3850946T3 (pl) 2024-03-11
HRP20190634T1 (hr) 2019-08-09
EP3850946A1 (en) 2021-07-21
PT3850946T (pt) 2024-01-02
CA2967834A1 (en) 2016-06-09
AU2015355328B2 (en) 2022-03-10
RU2728412C2 (ru) 2020-07-29
US12389889B2 (en) 2025-08-19
JP6730277B2 (ja) 2020-07-29
RU2017123357A (ru) 2019-01-09
HUE043132T2 (hu) 2019-07-29
CY1124089T1 (el) 2022-05-27
EP3466255B1 (en) 2021-02-17
DK3850946T5 (da) 2024-08-19
SMT202300482T1 (it) 2024-01-10
CN112342197A (zh) 2021-02-09
EP3850946B1 (en) 2023-09-27
CY1121547T1 (el) 2020-05-29
WO2016089692A1 (en) 2016-06-09
LT3850946T (lt) 2024-01-10
DK3086637T3 (en) 2019-04-08
NZ731471A (en) 2021-12-24
KR102313073B1 (ko) 2021-10-18

Similar Documents

Publication Publication Date Title
US12389889B2 (en) Mouse having a humanized cluster of differentiation 47 gene
AU2020286187B2 (en) Non-human animals having a humanized signal-regulatory protein gene
HK40096160A (en) Non-human animals having a humanized cluster of differentiation 47 gene
HK40054102A (en) Non-human animals having a humanized cluster of differentiation 47 gene
HK40054102B (en) Non-human animals having a humanized cluster of differentiation 47 gene
HK40007070B (en) Non-human animals having a humanized cluster of differentiation 47 gene
HK40007070A (en) Non-human animals having a humanized cluster of differentiation 47 gene
RU2827833C1 (ru) Животные, отличные от человека, имеющие гуманизированный ген кластера дифференцировки 47
HK1225912B (en) Non-human animals having a humanized cluster of differentiation 47 gene